Sjögren’s syndrome (SS) is a common autoimmune disease characterized by destruction and dysfunction of the salivary and lachrymal glands. Systemic manifestations occur in almost one third of patients with SS. Treatment of SS has been long considered as disappointing, being mainly restricted to local management with artificial tears and oral lubricants or to the use of immunosuppression-based therapies for systemic disease. Better knowledge of the pathogenesis of SS, including the role of retroviruses and cytokines and the discovery of aquaporins, provides new perspectives for the local and systemic management of this disease. Our goal is to focus on these recent therapeutic progresses.

1.
Jonsson R, Haga HJ, Gordon T: Sjögren’s syndrome; in Koopman WJ (ed): Arthritis and Allied Conditions – A Textbook of Rheumatology, ed 14. Philadelphia, Lippincott & Wilkins, 2001, pp 1736–1759.
2.
Provost TT, Watson R: Mucocutaneous manifestations of Sjögren’s syndrome; in Sontheimer RD, Provost TT (eds): Cutaneous Manifestations of Rheumatic Diseases, ed 1. Baltimore, Williams & Wilkins, 1996, pp 157–168.
3.
Dafni UG, Tzioufas AG, Staikos P, Skopouli FN, Moutsopoulos HM: Prevalence of Sjögren’s syndrome in a closed rural community. Ann Rheum Dis 1997;56:521–525.
4.
Whitacre CC: Sex differences in autoimmune disease. Nat Immunol 2001;2:777–780.
5.
Ioannidis JP, Vassiliou VA, Moutsopoulos HM: Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren’s syndrome. Arthritis Rheum 2002;46:741–747.
6.
Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH: Classification criteria for Sjögren’s syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554–558.
7.
Sall K, Stevenson OD, Mundorf TK, Reis BL: Two multicenter, randomized studies of the efficacy and safety of ophthalmic emulsion in moderate to severe dry eye disease. Ophtalmology 2000;107:631–639.
8.
Vivino FB, Al-Hashimi I, Khan Z, LeVeque FG, Salisbury PL, Tran-Johnson TK, Muscoplat CC, Trivedi M, Goldlust B, Gallagher SC: Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren’s syndrome: A randomized, placebo-controlled, fixed-dose, multicenter trial. Arch Intern Med 1999;159:174–181.
9.
Petrone D, Condemi JJ, Fife R, Gluck O, Cohen S, Dalgin P: A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren’s syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 2002;46:748–754.
10.
Fox RI, Chan E, Benton L, Fong S, Friedlander M, Howell FV: Treatment of primary Sjögren’s syndrome with hydroxychloroquine. Am J Med 1988;85:62–67.
11.
Kruize AA, Hene RJ, Kallenberg CG, van Bijsterveld OP, van der Heide A, Kater L, Bijlsma JW: Hydroxychloroquine treatment for primary Sjögren’s syndrome: A two year double blind crossover trial. Ann Rheum Dis 1993;52:360–364.
12.
Skopouli FN, Jagiello P, Tsifetaki N, Moutsopoulos HM: Methotrexate in primary Sjögren’s syndrome. Clin Exp Rheumatol 1996;14:555–558.
13.
Price EJ, Rigby SP, Clancy U, Venables PJW: A double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren’s syndrome. Arthritis Rheum 1998;25:896–899.
14.
Drosos AA, Skopouli FN, Costopoulos JS, Papadimitriou CS, Moutsopoulos HM: Cyclosporin A in primary Sjögren’s syndrome: A double-blind study. Ann Rheum Dis 1986;45:732–735.
15.
Brookes SM, Pandolfino YA, Mitchell TJ, Venables PJ, Shattles WG, Clark DA, Entwistle A, Maini RN: The immune response to and expression of cross-reactive retroviral gag sequences in autoimmune disease. Br J Rheumatol 1992;31:735–742.
16.
Shattles WG, Brookes SM, Venables PJ, Clark DA, Maini RN: Expression of antigen reactive with a monoclonal antibody to HTLV-1 P19 in salivary glands in Sjögren’s syndrome. Clin Exp Immunol 1992;89:46–51.
17.
Couderc LJ, D’Agay MF, Danon F, Harzic M, Brocheriou C, Clauvel JP: Sicca complex and infection with human immunodeficiency virus. Arch Intern Med 1987;147:898–901.
18.
Nakamura H, Kawakami A, Tominaga M, Hida A, Yamasaki S, Migita K, Kawabe Y, Nakamura T, Eguchi K: Relationship between Sjögren’s syndrome and human T-lymphotropic virus type I infection: Follow-up study of 83 patients. J Lab Clin Med 2000;135:139–144.
19.
Yamano S, Renard JN, Mizuno F, Narita Y, Uchida Y, Higashiyama H, Sakurai H, Saito I: Retrovirus in salivary glands from patients with Sjögren’s syndrome. J Clin Pathol 1997;50:223–230.
20.
Steinfeld SD, Demols P, Van Vooren JP, Cogan E, Appelboom T: Zidovudine in primary Sjögren’s syndrome. Rheumatology 1999;38:814–817.
21.
Cauli A, Yanni G, Pitzalis C, Challacombe S, Panayi GS: Cytokine and adhesion molecule expression in the minor salivary glands of patients with Sjögren’s syndrome and chronic sialoadenitis. Ann Rheum Dis 1995;54:209–215.
22.
Sun D, Emmert-Buck MR, Fox PC: Differential cytokine mRNA expression in human labial minor salivary glands in primary Sjögren’s syndrome. Autoimmunity 1998;28:125–137.
23.
Azuma M, Motegi K, Aota K, Hayashi Y, Sato M: Role of cytokines in the destruction of acinar structure in Sjögren’s syndrome salivary glands. Lab Invest 1997;77:269–280.
24.
Azuma M, Aota K, Tamatani T, Motegi K, Yamashita T, Harada K, Hayashi Y, Sato M: Suppression of tumor necrosis factor alpha-induced matrix metalloproteinase 9 production by the introduction of a super-repressor form of inhibitor of nuclear factor kappaBalpha complementary DNA into immortalized human salivary gland acinar cells: Prevention of the destruction of the acinar structure in Sjögren’s syndrome salivary glands. Arthritis Rheum 2000;43:1756–1767.
25.
Moser RB, Schleiffenbaum B, Groscurth P, Fehr J: Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage. J Clin Invest 1989;83:444–455.
26.
Brennan FM, Feldmann M: Cytokines in autoimmunity. Curr Opin Immunol 1996;8:872–877.
27.
Tornwald J, Fox H, Edwards C, Fox RI: Treatment with pegylated recombinant methionyl human soluble tumor necrosis factor-type 1 receptor prevents development of Sjögren’s syndrome and diabetes in NOD mouse model. Arthritis Rheum 1999;42:S403.
28.
Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T: Infliximab in patients with primary Sjögren’s syndrome: A pilot study. Arthritis Rheum 2001;44:2371–2375.
29.
Steinfeld SD, Demols P, Appelboom T: Infliximab in patients with primary Sjögren’s syndrome: One year follow-up. Arthritis Rheum 2002;46:3301–3303.
30.
Andoth Y, Shimura S, Sawai T, Sasaki H, Takishima T, Shirato K: Morphometric analysis of secretory glands in Sjögren’s syndrome. Am Rev Respir Dis 1993;148:1358–1362.
31.
Borgnia M, Nielsen S, Engel A, Agre P: Cellular and molecular biology of the aquaporin water channels. Annu Rev Biochem 1999;68:425–458.
32.
Ma T, Song Y, Gillespie A, Carlson EJ, Epstein CJ, Verkman AS: Defective secretion of saliva in transgenic mice lacking aquaporin-5 channels. J Biol Chem 1999;274:20071–20074.
33.
Steinfeld S, Cogan E, King LS, Agre P, Kiss R, Delporte C: Abnormal distribution of aquaporin-5 water channel protein in salivary glands from Sjögren’s syndrome patients. Lab Invest 2001;81:143–148.
34.
Tsubota K, Hirai S, King LS, Agre P, Ishida N: Defective cellular trafficking of lacrimal gland aquaporin 5 in Sjögren’s syndrome. Lancet 2001;357:688–689.
35.
Nejsum LN, Kwon TH, Jensen UB, Fumagalli O, Frokiaer J, Krane CM, Menon AG, King LS, Agre PC, Nielsen S: Functional requirement of aquaporin 5 in plasma membranes of sweat glands. Proc Natl Acad Sci USA 2002;99:511–516.
36.
Delporte C, O’Connell BC, He X, Lancaster H, O’Connell A, Agre P, Baum BJ: Increased fluid secretion following transfer of the aquaporin 1 cDNA to irradiated rat salivary glands. Proc Natl Acad Sci USA 1997;94:3268–3273.
37.
Towne JE, Krane CM, Bachrski CJ, Menon AG: Tumor necrosis factor-α inhibits aquaporin 5 expression in mouse lung epithelial cells. J Biol Chem 2001;276:18657–18664.
38.
Steinfeld S, Appelboom T, Delporte C: Treatment with infliximab restored normal aquaporin 5 distribution in minor salivary glands of Sjögren’s syndrome patients. Arthritis Rheum 2002;46:2249–2251.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.